Ihya Fakhrurizal Amin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ihya Fakhrurizal Amin has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Mohamad Amin
Universitas Negeri Malang
5 shared publications - Afid Brilliana Putra
Faculty of Medicine Universitas Indonesia
2 shared publications Ahya Zhilalikbar Amin
Department of Biosciences, Faculty of Science, Universiti Teknologi Malaysia, Johor, Malaysia
2 shared publicationsDina Maulina
2 shared publications- Dina Maulina
Universitas Lampung
2 shared publications - Erlina Burhan
Respiratory Programmatic Implementation and Research Institute, Jakarta, Indonesia
2 shared publications
Latest Publications
- Open Access
- 30 June 2024
- Published by Pakistan Society of Neurology in Pakistan Journal of Neurological Sciences
- Vol. 19 (02)
Neurocognitive Outcome Following Tuberculous Meningitis Treatment : A Systematic Review
Background and objective: Tuberculous meningitis (TBM) is an infectious disease of the central nervous system that remains to be a global health challenge. Patients who survive after experiencing TBM have a risk of developing functional, cognitive and psychological disorders that can affect daily activities. The objective of this study is to present a comprehensive review of data on cognitive outcome after TBM infection. Method: We conducted a systematic literature search to identify studies addressing cognitive outcomes in adult TBM patients. Following a systematic literature search (PubMed, Scopus, EBSCO), studies were reviewed by independent reviewers to assess eligibility for inclusion. Three independent reviewers extracted data from included studies. Result: Among the articles identified, 6 studies met inclusion criteria, reporting cognitive outcomes for 330 patients with TBM. All studies followed the patients for 12 months or more. Three studies used Mini-Mental State Examinations (MMSE) to assess cognitive function, while other studies used a variety of tools: HIV-associated neurocognitive disorder (HAND), Montreal Cognitive Assessment (MoCA), neuropsychological (NEUROPSI), and Wechsler Adult Intelligence Scale (WAIS). All studies reported an improvement in cognitive function after completion of TB therapy. Two studies compared TBM with HIV, and showed TBM patients with HIV had worse cognitive outcomes than those without HIV. Conclusion: Cognitive function assessment tools in TBM patients are diverse and after approximately 12 months of follow-up following TB therapy, there was improvement in cognitive function. Standardized reporting of cognitive outcomes will be essential to improve data quality and data-sharing potential.
- 30 June 2024
- Published by Pakistan Society of Neurology in Pakistan Journal of Neurological Sciences
- Vol. 19 (02)
Open AccessNeurocognitive Outcome Following Tuberculous Meningitis Treatment : A Systematic Review
Background and objective: Tuberculous meningitis (TBM) is an infectious disease of the central nervous system that remains to be a global health challenge. Patients who survive after experiencing TBM have a risk of developing functional, cognitive and psychological disorders that can affect daily activities. The objective of this study is to present a comprehensive review of data on cognitive outcome after TBM infection. Method: We conducted a systematic literature search to identify studies addressing cognitive outcomes in adult TBM patients. Following a systematic literature search (PubMed, Scopus, EBSCO), studies were reviewed by independent reviewers to assess eligibility for inclusion. Three independent reviewers extracted data from included studies. Result: Among the articles identified, 6 studies met inclusion criteria, reporting cognitive outcomes for 330 patients with TBM. All studies followed the patients for 12 months or more. Three studies used Mini-Mental State Examinations (MMSE) to assess cognitive function, while other studies used a variety of tools: HIV-associated neurocognitive disorder (HAND), Montreal Cognitive Assessment (MoCA), neuropsychological (NEUROPSI), and Wechsler Adult Intelligence Scale (WAIS). All studies reported an improvement in cognitive function after completion of TB therapy. Two studies compared TBM with HIV, and showed TBM patients with HIV had worse cognitive outcomes than those without HIV. Conclusion: Cognitive function assessment tools in TBM patients are diverse and after approximately 12 months of follow-up following TB therapy, there was improvement in cognitive function. Standardized reporting of cognitive outcomes will be essential to improve data quality and data-sharing potential.
- Open Access
- 23 November 2023
- Published by Springer Nature in Research Square
Neurocognitive Outcome Following Tuberculous Meningitis Treatment in Adults: A Systematic Review
Background Tuberculous meningitis (TBM) is an infectious diseases of the central nervous system that are still a global health challenge, including Indonesia. Patients who survive after experiencing TBM have a risk of functional, neurocognitive and psychological disorders that will affect daily activities. The aim of this study is to present a comprehensive review of data on neurocognitive outcome after TBM infection in adults.Method We conducted a systematic literature search to identify studies addressing cognitive outcomes in adult TBM patients. Following a systematic literature search (Pubmed, Scopus, Ebsco), studies underwent duplicate screening by independent reviewers to assess eligibility for inclusion. Three independent reviewers extracted data from included studies.Result Among the article identified, 7 studies met our inclusion criteria, reporting on cognitive outcomes for 364 adults with TBM. All studies followed the patients for 12 months or more. Three studies used Mini-Mental State Examinations (MMSE) to assess cognitive function, while other studies used a variety of tools: HIV-associated neurocognitive disorder (HAND), Montreal Cognitive Assessment (MoCA), neuropsychological (NEUROPSI), and Wechsler Adult Intelligence Scale (WAIS). All studies reported an improvement in cognitive function after completion of TB therapy. Two studies comparing TBM with HIV, and showed TBM patients with HIV had worse cognitive outcomes than those without HIV.Conclusion Cognitive function assessment tools in TBM patients are diverse and after approximately 12 months of follow-up in patients on TB therapy, there was improvement in cognitive function. Standardized reporting of neurocognitive outcomes will be essential to improve data quality and data-sharing potential.
- 23 November 2023
- Published by Springer Nature in Research Square
Open AccessNeurocognitive Outcome Following Tuberculous Meningitis Treatment in Adults: A Systematic Review
Background Tuberculous meningitis (TBM) is an infectious diseases of the central nervous system that are still a global health challenge, including Indonesia. Patients who survive after experiencing TBM have a risk of functional, neurocognitive and psychological disorders that will affect daily activities. The aim of this study is to present a comprehensive review of data on neurocognitive outcome after TBM infection in adults.Method We conducted a systematic literature search to identify studies addressing cognitive outcomes in adult TBM patients. Following a systematic literature search (Pubmed, Scopus, Ebsco), studies underwent duplicate screening by independent reviewers to assess eligibility for inclusion. Three independent reviewers extracted data from included studies.Result Among the article identified, 7 studies met our inclusion criteria, reporting on cognitive outcomes for 364 adults with TBM. All studies followed the patients for 12 months or more. Three studies used Mini-Mental State Examinations (MMSE) to assess cognitive function, while other studies used a variety of tools: HIV-associated neurocognitive disorder (HAND), Montreal Cognitive Assessment (MoCA), neuropsychological (NEUROPSI), and Wechsler Adult Intelligence Scale (WAIS). All studies reported an improvement in cognitive function after completion of TB therapy. Two studies comparing TBM with HIV, and showed TBM patients with HIV had worse cognitive outcomes than those without HIV.Conclusion Cognitive function assessment tools in TBM patients are diverse and after approximately 12 months of follow-up in patients on TB therapy, there was improvement in cognitive function. Standardized reporting of neurocognitive outcomes will be essential to improve data quality and data-sharing potential.
- Open Access
- 15 November 2023
- Published by Springer Nature in Research Square
Adalimumab as Therapy for Hidradenitis Suppurativa: a Systematic Review
Background Adalimumab (ADA) is a monoclonal antibody that is widely used as a biologic therapy for immune diseases, one of which is hidradenitis suppurativa (HS). To date, evidence-based therapeutic approaches have not been commonly used for standard of care and this is likely due to the lack of related research and the diverse therapeutic options. ADA biologic therapy shows satisfactory results and is approved by the FDA for moderate to severe HS in adult patients. Purpose: To provide an overview of the current evidence regarding the treatment of HS with ADA. Methods A literature search related to Hidradenitis Suppurativa Clinical Response (HiSCR) was performed on the PubMed, Scopus, and EbscoHost databases with an ADA focus on HS treatment to achieve HiSCR. Full text analysis of 8 RCT studies that met the inclusion and exclusion criteria and used a critically reviewed questionnaire from the CEBM University of Oxford. Result In this systematic review we obtained 8 RCTs for evaluation. The results showed that the prevalence of HiSCR after exposure to high doses of ADA, this statement was supported by 4 studies of RR > 1, meaning that the addition of ADA gave patients more opportunities to achieve HiSCR. Another finding was a decrease in Sartorius scores and DLQI after ADA treatment. ADA can reduce depressive symptoms and increase pain, this statement is supported by two studies using the PHQ and PGA-SP scores. Conclusion ADA has good efficacy against HS, as evidenced by the high prevalence of HiSCR and quality of life of patients.
- 15 November 2023
- Published by Springer Nature in Research Square
Open AccessAdalimumab as Therapy for Hidradenitis Suppurativa: a Systematic Review
Background Adalimumab (ADA) is a monoclonal antibody that is widely used as a biologic therapy for immune diseases, one of which is hidradenitis suppurativa (HS). To date, evidence-based therapeutic approaches have not been commonly used for standard of care and this is likely due to the lack of related research and the diverse therapeutic options. ADA biologic therapy shows satisfactory results and is approved by the FDA for moderate to severe HS in adult patients. Purpose: To provide an overview of the current evidence regarding the treatment of HS with ADA. Methods A literature search related to Hidradenitis Suppurativa Clinical Response (HiSCR) was performed on the PubMed, Scopus, and EbscoHost databases with an ADA focus on HS treatment to achieve HiSCR. Full text analysis of 8 RCT studies that met the inclusion and exclusion criteria and used a critically reviewed questionnaire from the CEBM University of Oxford. Result In this systematic review we obtained 8 RCTs for evaluation. The results showed that the prevalence of HiSCR after exposure to high doses of ADA, this statement was supported by 4 studies of RR > 1, meaning that the addition of ADA gave patients more opportunities to achieve HiSCR. Another finding was a decrease in Sartorius scores and DLQI after ADA treatment. ADA can reduce depressive symptoms and increase pain, this statement is supported by two studies using the PHQ and PGA-SP scores. Conclusion ADA has good efficacy against HS, as evidenced by the high prevalence of HiSCR and quality of life of patients.
- Open Access
- 13 November 2023
- Published by Hindawi Limited in Case Reports in Medicine
- Vol. 2023, 1-6
Cytomegalovirus Infection in Patient with Clear Cell Renal Cell Carcinoma
Introduction. Cytomegalovirus (CMV) infection is a widespread condition that can affect individuals of all ages. Most cases of CMV infection are mild and resolve on their own. However, in immunocompromised individuals, such as post-transplant patients or those with cancer, severe infections can occur. While there have been several studies on CMV infection in post-transplant patients, there is limited literature on CMV infection in cancer, particularly in kidney cancer. Case Report. In this case report, we present the case of a 61-year-old man with clear cell renal cell carcinoma who underwent targeted therapy with the receptor tyrosine kinase (RTK) inhibitor lenvatinib and the mammalian target of rapamycin (mTOR) inhibitor everolimus. The patient was hospitalized for 26days and admitted to the intensive care unit (ICU) due to shortness of breath, decreased oxygen saturation, and irregular breathing. Cytomegalovirus polymerase chain reaction (PCR) test results were positive. Given the high prevalence of CMV infection in developing countries, it is likely that the patient had a reactivation of CMV. As such, the patient was subsequently treated with ganciclovir for 14days and showed improvement in symptoms such as shortness of breath, cough, fever, and increased oxygen saturation. Following recovery, the patient received maintenance therapy with oral valganciclovir for 7days. No further symptoms appeared during subsequent cancer treatments. Conclusion. Cancer patients who are undergoing treatment are at a higher risk for developing opportunistic infections, which can result in morbidity and mortality. Therefore, healthcare professionals should be aware of the possibility of CMV infection in cancer patients and be prepared to diagnose and treat the infection, particularly in areas where the prevalence of CMV infection is high.
- 13 November 2023
- Published by Hindawi Limited in Case Reports in Medicine
- Vol. 2023, 1-6
Open AccessCytomegalovirus Infection in Patient with Clear Cell Renal Cell Carcinoma
Introduction. Cytomegalovirus (CMV) infection is a widespread condition that can affect individuals of all ages. Most cases of CMV infection are mild and resolve on their own. However, in immunocompromised individuals, such as post-transplant patients or those with cancer, severe infections can occur. While there have been several studies on CMV infection in post-transplant patients, there is limited literature on CMV infection in cancer, particularly in kidney cancer. Case Report. In this case report, we present the case of a 61-year-old man with clear cell renal cell carcinoma who underwent targeted therapy with the receptor tyrosine kinase (RTK) inhibitor lenvatinib and the mammalian target of rapamycin (mTOR) inhibitor everolimus. The patient was hospitalized for 26days and admitted to the intensive care unit (ICU) due to shortness of breath, decreased oxygen saturation, and irregular breathing. Cytomegalovirus polymerase chain reaction (PCR) test results were positive. Given the high prevalence of CMV infection in developing countries, it is likely that the patient had a reactivation of CMV. As such, the patient was subsequently treated with ganciclovir for 14days and showed improvement in symptoms such as shortness of breath, cough, fever, and increased oxygen saturation. Following recovery, the patient received maintenance therapy with oral valganciclovir for 7days. No further symptoms appeared during subsequent cancer treatments. Conclusion. Cancer patients who are undergoing treatment are at a higher risk for developing opportunistic infections, which can result in morbidity and mortality. Therefore, healthcare professionals should be aware of the possibility of CMV infection in cancer patients and be prepared to diagnose and treat the infection, particularly in areas where the prevalence of CMV infection is high.
- Open Access
- 1 January 2023
- Published by AIP Publishing in AIP Conference Proceedings
- Vol. 2748 (1)
In silico analysis of tetrahydroxycurcumin compound in tumeric (Curcuma longa) as inhibitor of SARS-CoV-2 virus replication
There are many uses of natural ingredients to find out their potential in overcoming Coronavirus Disease 2019. One of the plants that is often used to treat various diseases, including SARS-Cov2 infection is turmeric. Turmeric contains Tetrahydroxycurcumin compounds. The aim of this research was to study the potential of Tetrahydroxycurcumin in preventing infection with the SARS-CoV-2 virus. The results showed that Tetrahydroxicurcumin has the potential to inhibit Tyrosine protein kinase ABL1, which is a protein that plays a role in the preparation of the cytoskeleton during viral infection. The binding affinity of Tetrahydroxycurcumin for this protein is -8.4 kcal/mol.
- 1 January 2023
- Published by AIP Publishing in AIP Conference Proceedings
- Vol. 2748 (1)
Open AccessIn silico analysis of tetrahydroxycurcumin compound in tumeric (Curcuma longa) as inhibitor of SARS-CoV-2 virus replication
There are many uses of natural ingredients to find out their potential in overcoming Coronavirus Disease 2019. One of the plants that is often used to treat various diseases, including SARS-Cov2 infection is turmeric. Turmeric contains Tetrahydroxycurcumin compounds. The aim of this research was to study the potential of Tetrahydroxycurcumin in preventing infection with the SARS-CoV-2 virus. The results showed that Tetrahydroxicurcumin has the potential to inhibit Tyrosine protein kinase ABL1, which is a protein that plays a role in the preparation of the cytoskeleton during viral infection. The binding affinity of Tetrahydroxycurcumin for this protein is -8.4 kcal/mol.
- Open Access
- 14 July 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (14) , 4070
Comparison of the Efficacy and Safety of Rivaroxaban and Enoxaparin as Thromboprophylaxis Agents for Orthopedic Surgery—Systematic Review and Meta-Analysis
Venous thromboembolism (VTE) is a serious complication that can occur during and after postoperative treatment, including in treatment after orthopedic surgery. The current guidelines for VTE prophylaxis in postoperative patients recommend the use of LMWHs, one of which is enoxaparin. Another recommendation for use in pharmacological VTE prophylaxis is rivaroxaban, which has better efficacy than enoxaparin but a higher bleeding risk. The aim of this systematic review is to provide an update on the profile of rivaroxaban for VTE prophylaxis after orthopedic surgery. PubMed, SCOPUS, EMBASE, and EBSCOhost were searched up until May 2022. The outcome sought was efficacy and safety, described by the incidence of VTE and incidence of bleeding, respectively. Five randomized controlled trials (RCT) were finally included. Rivaroxaban was confirmed to have better efficacy by significantly reducing the risk of VTE and all-cause mortality (RR = 0.38; 95% CI = 0.27–0.54) compared to enoxaparin. However, regarding the safety variable, no significant difference was found between the incidence of major bleeding in rivaroxaban and enoxaparin (RR = 0.97; 95% CI = 0.56–1.68). The results of the analysis show that rivaroxaban has better efficacy than enoxaparin but the same safety profile, so when used, the bleeding of patients should still be monitored.
- 14 July 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (14) , 4070
Open AccessComparison of the Efficacy and Safety of Rivaroxaban and Enoxaparin as Thromboprophylaxis Agents for Orthopedic Surgery—Systematic Review and Meta-Analysis
Venous thromboembolism (VTE) is a serious complication that can occur during and after postoperative treatment, including in treatment after orthopedic surgery. The current guidelines for VTE prophylaxis in postoperative patients recommend the use of LMWHs, one of which is enoxaparin. Another recommendation for use in pharmacological VTE prophylaxis is rivaroxaban, which has better efficacy than enoxaparin but a higher bleeding risk. The aim of this systematic review is to provide an update on the profile of rivaroxaban for VTE prophylaxis after orthopedic surgery. PubMed, SCOPUS, EMBASE, and EBSCOhost were searched up until May 2022. The outcome sought was efficacy and safety, described by the incidence of VTE and incidence of bleeding, respectively. Five randomized controlled trials (RCT) were finally included. Rivaroxaban was confirmed to have better efficacy by significantly reducing the risk of VTE and all-cause mortality (RR = 0.38; 95% CI = 0.27–0.54) compared to enoxaparin. However, regarding the safety variable, no significant difference was found between the incidence of major bleeding in rivaroxaban and enoxaparin (RR = 0.97; 95% CI = 0.56–1.68). The results of the analysis show that rivaroxaban has better efficacy than enoxaparin but the same safety profile, so when used, the bleeding of patients should still be monitored.
- Open Access
- 25 March 2021
- Published by Faculty of Medicine, Universitas Indonesia in Medical Journal of Indonesia
- Vol. 30 (1) , 5-12
Elevated extracellular CO2 level affects the adaptive transcriptional response and survival of human peripheral blood mononuclear cells toward hypoxia and oxidative stress
BACKGROUND High carbon dioxide (CO2) level from indoor environments, such as classrooms and offices, might cause sick building syndrome. Excessive indoor CO2 level increases CO2 level in the blood, and over-accumulation of CO2 induces an adaptive response that requires modulation of gene expression. This study aimed to investigate the adaptive transcriptional response toward hypoxia and oxidative stress in human peripheral blood mononuclear cells (PBMCs) exposed to elevated CO2 level in vitro and its association with cell viability. METHODS PBMCs were treated in 5% CO2 and 15% CO2, representatives a high CO₂ level condition for 24 and 48 hours. Extracellular pH (pHe) was measured with a pH meter. The levels of reactive oxygen species were determined by measuring superoxide and hydrogen peroxide with dihydroethidium and dichlorofluorescin-diacetate assay. The mRNA expression levels of hypoxia-inducible factor (HIF)-1α, HIF-2α, nuclear factor (NF)-κB, and manganese superoxide dismutase (MnSOD) were analyzed using a real-time reverse transcriptase-polymerase chain reaction (qRT-PCR). Cell survival was determined by measuring cell viability. RESULTS pHe increased in 24 hours after 15% CO₂ treatment, and then decreased in 48 hours. Superoxide and hydrogen peroxide levels increased after the 24- and 48-hour of high CO₂ level condition. The expression levels of NF-κB, MnSOD, HIF-1α, and HIF-2α decreased in 24 hours and increased in 48 hours. The increased antioxidant mRNA expression in 48 hours showed that the PBMCs were responsive under high CO2 conditions. Elevated CO2 suppressed cell viability significantly in 48 hours. CONCLUSIONS After 48 hours of high CO₂ level condition, PBMCs showed an upregulation in genes related to hypoxia and oxidative stress to overcome the effects of CO2 elevation.
- 25 March 2021
- Published by Faculty of Medicine, Universitas Indonesia in Medical Journal of Indonesia
- Vol. 30 (1) , 5-12
Open AccessElevated extracellular CO2 level affects the adaptive transcriptional response and survival of human peripheral blood mononuclear cells toward hypoxia and oxidative stress
BACKGROUND High carbon dioxide (CO2) level from indoor environments, such as classrooms and offices, might cause sick building syndrome. Excessive indoor CO2 level increases CO2 level in the blood, and over-accumulation of CO2 induces an adaptive response that requires modulation of gene expression. This study aimed to investigate the adaptive transcriptional response toward hypoxia and oxidative stress in human peripheral blood mononuclear cells (PBMCs) exposed to elevated CO2 level in vitro and its association with cell viability. METHODS PBMCs were treated in 5% CO2 and 15% CO2, representatives a high CO₂ level condition for 24 and 48 hours. Extracellular pH (pHe) was measured with a pH meter. The levels of reactive oxygen species were determined by measuring superoxide and hydrogen peroxide with dihydroethidium and dichlorofluorescin-diacetate assay. The mRNA expression levels of hypoxia-inducible factor (HIF)-1α, HIF-2α, nuclear factor (NF)-κB, and manganese superoxide dismutase (MnSOD) were analyzed using a real-time reverse transcriptase-polymerase chain reaction (qRT-PCR). Cell survival was determined by measuring cell viability. RESULTS pHe increased in 24 hours after 15% CO₂ treatment, and then decreased in 48 hours. Superoxide and hydrogen peroxide levels increased after the 24- and 48-hour of high CO₂ level condition. The expression levels of NF-κB, MnSOD, HIF-1α, and HIF-2α decreased in 24 hours and increased in 48 hours. The increased antioxidant mRNA expression in 48 hours showed that the PBMCs were responsive under high CO2 conditions. Elevated CO2 suppressed cell viability significantly in 48 hours. CONCLUSIONS After 48 hours of high CO₂ level condition, PBMCs showed an upregulation in genes related to hypoxia and oxidative stress to overcome the effects of CO2 elevation.
- 2 June 2020
- Published by AIP Publishing in AIP Conference Proceedings
- Vol. 2237 (1) , 020072
Chemical interaction analysis of L-Theanine compounds from Camellia sinensis L. with kainate glutamate receptors and their toxicity effect as anti autism candidates based on in silico
Autism is a neuropsychiatric disease; one of the causes of autism is damage to neurons. L-Theanine is a bioactive compound in Camellia sinensis L.which is analogous to L-Glutamate Acid structure and its neuroprotective effect. This study aimed to analyze the binding side of L-Theanine and L-Glutamate Acid to the kainate of glutamate receptor protein to determine and the effectiveness of its inhibitor function. Toxicity analysis is also used to determine the suitability of compounds as bioactive components to be consumed orally. The method used to analyze the interaction of compounds with target proteins is reverse docking. Toxicity analysis using the Toxtree 2.6.13 and collection of information from the Human Metabolome Database. The docking shows that L-Glutamate Acid and L-Theanine have the same site in the ionotropic Glutamate receptor protein, kainate1. The residual groups of the two compounds when binding to the similar glutamate receptor protein are THR (A: 91), GLU (A: 191), and ARG (A: 96). The binding affinity of the two compounds is almost the same, namely -5.0 kcal/mol for L-Glutamate Acid and -4.9 kcal/mol for L-Theanine. This allows L-Theanine to act as an inhibitor that blocks L-Glutamate Acid from binding to glutamate receptors on prostsynap membranes. The compound docking results show that L-Theanine has four bond side residues that are the same as the same L-Glutamate Acid and binding affinity of -5.0 kcal/mol. Analysis with the principle of RO5 Lipinski is known that L-Theanine compounds have the potential if taken orally. Therefore, the C. sinensis L. potential as an anti-autism substance.
- 2 June 2020
- Published by AIP Publishing in AIP Conference Proceedings
- Vol. 2237 (1) , 020072
Chemical interaction analysis of L-Theanine compounds from Camellia sinensis L. with kainate glutamate receptors and their toxicity effect as anti autism candidates based on in silico
Autism is a neuropsychiatric disease; one of the causes of autism is damage to neurons. L-Theanine is a bioactive compound in Camellia sinensis L.which is analogous to L-Glutamate Acid structure and its neuroprotective effect. This study aimed to analyze the binding side of L-Theanine and L-Glutamate Acid to the kainate of glutamate receptor protein to determine and the effectiveness of its inhibitor function. Toxicity analysis is also used to determine the suitability of compounds as bioactive components to be consumed orally. The method used to analyze the interaction of compounds with target proteins is reverse docking. Toxicity analysis using the Toxtree 2.6.13 and collection of information from the Human Metabolome Database. The docking shows that L-Glutamate Acid and L-Theanine have the same site in the ionotropic Glutamate receptor protein, kainate1. The residual groups of the two compounds when binding to the similar glutamate receptor protein are THR (A: 91), GLU (A: 191), and ARG (A: 96). The binding affinity of the two compounds is almost the same, namely -5.0 kcal/mol for L-Glutamate Acid and -4.9 kcal/mol for L-Theanine. This allows L-Theanine to act as an inhibitor that blocks L-Glutamate Acid from binding to glutamate receptors on prostsynap membranes. The compound docking results show that L-Theanine has four bond side residues that are the same as the same L-Glutamate Acid and binding affinity of -5.0 kcal/mol. Analysis with the principle of RO5 Lipinski is known that L-Theanine compounds have the potential if taken orally. Therefore, the C. sinensis L. potential as an anti-autism substance.
- Open Access
- 10 April 2020
- Published by Al-Jamiah Research Centre in Biology, Medicine, & Natural Product Chemistry
- Vol. 9 (1) , 27-32
The Potential of Chrysin of Oroxylum indicum L. to Induce Carbonic Anhydrase (CA) to Improve Cattle Fertility
The Artificial Insemination (AI) aims to develop the potential of the cattle reproduction comprehensively. The success of AI results is highly dependent on the level of livestock fertility. Therefore, improv the quality and quantity of semen could be done by hormone induction. However, hormone prices are expensive. This problem could be overcome using alternative way with the natural compound containing chrysin which might has the same function. The purpose of the study was analyze the potential of chrysin compound from Bungli plant (Oroxylum indicum) as fertilizer of males through bioinformatics approach. Methods performed through data search by webserver with the following stages: (1) Pubchem, (2) Swiss (3) Target Prediction, (4) Uniprot, (5) Protein Data Bank and (6) docking software using PyRx, PyMOL and Discovery Studio. The results showed that the chrysin compound interact with carbonic anhydrase (CA) expressed from the testes of the cattle, through van der Waals and Pi-Alkyl bonds. Chrysin is effective as CA ligand inducers based on affinity bonds (-8.4 kcal/mole) and more negatively than flavonol as a control compound with binding affinity (-6.2 kcal/mol). This suggests that chrysin is an effective compound as a potential drug for improved livestock fertility.
- 10 April 2020
- Published by Al-Jamiah Research Centre in Biology, Medicine, & Natural Product Chemistry
- Vol. 9 (1) , 27-32
Open AccessThe Potential of Chrysin of Oroxylum indicum L. to Induce Carbonic Anhydrase (CA) to Improve Cattle Fertility
The Artificial Insemination (AI) aims to develop the potential of the cattle reproduction comprehensively. The success of AI results is highly dependent on the level of livestock fertility. Therefore, improv the quality and quantity of semen could be done by hormone induction. However, hormone prices are expensive. This problem could be overcome using alternative way with the natural compound containing chrysin which might has the same function. The purpose of the study was analyze the potential of chrysin compound from Bungli plant (Oroxylum indicum) as fertilizer of males through bioinformatics approach. Methods performed through data search by webserver with the following stages: (1) Pubchem, (2) Swiss (3) Target Prediction, (4) Uniprot, (5) Protein Data Bank and (6) docking software using PyRx, PyMOL and Discovery Studio. The results showed that the chrysin compound interact with carbonic anhydrase (CA) expressed from the testes of the cattle, through van der Waals and Pi-Alkyl bonds. Chrysin is effective as CA ligand inducers based on affinity bonds (-8.4 kcal/mole) and more negatively than flavonol as a control compound with binding affinity (-6.2 kcal/mol). This suggests that chrysin is an effective compound as a potential drug for improved livestock fertility.
- Open Access
- 19 June 2018
- Published by Knowledge E DMCC in KnE Life Sciences
- Vol. 4 (5) , 592-598
Eicosapentaenoic Acid (EPA) from Fish Oil and Margarine as Bioactive Compound for Anti-inflammation in Occupational Dermatitis
Eicosapentaenoic Acid (EPA) from Fish Oil and Margarine as Bioactive Compound for Anti-inflammation in Occupational Dermatitis
- 19 June 2018
- Published by Knowledge E DMCC in KnE Life Sciences
- Vol. 4 (5) , 592-598
Open AccessEicosapentaenoic Acid (EPA) from Fish Oil and Margarine as Bioactive Compound for Anti-inflammation in Occupational Dermatitis
Eicosapentaenoic Acid (EPA) from Fish Oil and Margarine as Bioactive Compound for Anti-inflammation in Occupational Dermatitis